Product Description
KRRO-110 is the first RNA editing oligonucleotide candidate from Korro’s proprietary OPERA™ platform. Korro has demonstrated the ability to repair the misfolding of the Alpha-1 Antitrypsin (A1AT) protein containing the Z mutation, as well as reduce liver aggregates, in a preclinical mouse model. (Sourced from: https://www.korrobio.com/press-releases/korro-announces-selection-of-its-first-development-candidate-for-the-potential-treatment-of-alpha-1-antitrypsin-deficiency-aatd/)
Mechanisms of Action: SERPINA1
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Korro Bio
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: alpha 1-Antitrypsin Deficiency
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| REWRITE | P2 |
Recruiting |
alpha 1-Antitrypsin Deficiency |
2026-12-01 |